Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma.

Abstract

The expression patterns and prognostic significance of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) protein in the neoplastic Hodgkin and Reed Sternberg (HRS) cells of Hodgkin lymphoma (HL) were investigated in a cohort of 154 patients with HL treated with standard regimens. SAMHD1 expression was assessed by immunohistochemistry using diagnostic lymph node biopsies obtained prior to treatment. Using an arbitrary 20% cut-off, SAMHD1 was positive in HRS cells of 48/154 (31·2%) patients. SAMHD1 expression was not associated with clinicopathologic parameters, such as age, gender, stage or histologic subtype. In 125 patients with a median follow-up of 90 months (7-401 months), SAMHD1 expression in HRS cells significantly correlated with inferior freedom from progression (FFP) (P = 0·025), disease-specific survival (DSS) (P = 0·013) and overall survival (OS) (P = 0·01). Importantly, in multivariate models together with disease stage, histology subtype and type of treatment as covariates, SAMHD1 expression retained an independent significant association with unfavourable FFP (P = 0·005) as well as DSS (P = 0·022) and OS (P = 0·018). These findings uncover the significance of a novel, adverse prognostic factor in HL that may have therapeutic implications since SAMHD1 inhibitors are now available for clinical use.

• Authors: Ioanna Xagoraris, Theodoros P Vassilakopoulos, Elias Drakos, Maria K Angelopoulou, Fotios Panitsas, Nikolas Herold, L Jeffrey Medeiros, Xanthoula Giakoumis, Gerassimos A Pangalis, George Z Rassidakis
• Journal: British journal of haematology (Br J Haematol) Vol. 193 Issue 3 Pg. 488-496 (05 2021) ISSN: 1365-2141 [Electronic] England
• PMID: 33528031 (Publication Type: Clinical Trial, Journal Article)
• Copyright: © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Chemical References

• Bleomycin
• Vinblastine
• Dacarbazine
• Doxorubicin
• SAM Domain and HD Domain-Containing Protein 1
• SAMHD1 protein, human

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Bleomycin (administration & dosage)
• Cell Line, Tumor
• Dacarbazine (administration & dosage)
• Disease-Free Survival
• Doxorubicin (administration & dosage)
• Female
• Follow-Up Studies
• Gene Expression Regulation, Enzymologic (drug effects)
• Gene Expression Regulation, Neoplastic (drug effects)
• Hodgkin Disease (drug therapy, enzymology, mortality)
• Humans
• Lymph Nodes (enzymology)
• Male
• Middle Aged
• Neoplasm Staging
• SAM Domain and HD Domain-Containing Protein 1 (biosynthesis)
• Survival Rate
• Vinblastine (administration & dosage)